Potential impact of sulfonylureas in the outcome of type 2 diabetic patients with ischemic stroke

Stroke

Volumn 38, Issue 9, 2007, Pages 2413-2414

  Arboix, Adrià ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Cerebral infarction; Diabetes mellitus; Stroke management; Stroke outcome; Sulfonylurea compounds; Type 2

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLIBENCLAMIDE; GLIBORNURIDE; GLIMEPIRIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SULFONYLUREA DERIVATIVE; SULFONYLUREA RECEPTOR;

BRAIN HEMORRHAGE; BRAIN INFARCTION; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DRUG MECHANISM; EDITORIAL; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; ISCHEMIC HEART DISEASE; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RANKIN SCALE; TRANSIENT ISCHEMIC ATTACK;

BRAIN EDEMA; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS, TYPE 2; HUMANS; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; SULFONYLUREA COMPOUNDS; TREATMENT OUTCOME;

EID: 34548220992     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.107.488361     Document Type: Editorial

References (18)

1. Lukovits TG, Mazzone TM, Gorelick TM. Diabetes mellitus and cerebrovascular disease. Neuroepidemiology. 1999;18:1-4.
2. Mankovsky BN, Metzger BE, Molitch ME, Biller J. Cerebrovascular disorders in patients with diabetes mellitus. J Diab Comp. 1996;10:228-242.
3. Arboix A, Rivas A, Garcia-Eroles L, de Marcos L, Massons J, Oliveres M. Cerebral infarction in diabetes: clinical pattern, stroke subtypes, and predictors of in-hospital mortality. BMC Neurol. 2005;5:9.
4. Megherbi SE, Milan C, Minier D, Couvreur G, Osseby GV, Tilling K, Di Carlo A, Inzitari D, Wolfe CD, Moreau T, Giroud M; European BIOMED Study of Stroke Care Group. Association between diabetes and stroke subtype on survival and functional outcome 3 months after stroke: data from the European BIOMED Stroke Project. Stroke. 2003;34:688-694.
5. Arboix A, Milian M, Oliveres M, Garcia-Eroles L, Massons J. Impact of female gender on prognosis of type 2 diabetic patients with ischemic stroke. Eur Neurol. 2006;56:6-12.
6. Arboix A, Massons J, Garcia-Eroles L, Oliveres M, Targa C. Diabetes is an independent risk factor for in-hospital mortality from acute spontaneous intracerebral hemorrhage. Diabetes Care. 2000;23:1527-1532.
7. Zhu CZ, Auer RN. Optimal blood glucose levels while using insulin to minimize the size of infarction in focal cerebral ischemia. J Neurosurg. 2004;101:664-668.
8. Simard JM, Kent TA, Chen M, Tarasov KV, Gerzanich V. Brain oedema in focal ischaemia: molecular pathophysiology and theoretical implications. Lancet Neurol. 2007;6:258-268.
9. Simard JM, Chen M, Tarasov KV, Bhatta S, Ivanova S, Melnitchenko L, Tsymbalyuk N, West GA, Gerzanich V. Newly expressed SUR1-regulated NC(Ca-ATP) channel mediates cerebral edema after ischemic stroke. Nat Med. 2006;12:433- 440.
10. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 2005;365:1333-1346.
11. Kunte H, Schmidt S, Eliasziw M, del Zoopo GJ, Simard JM, Masuhr F, Weih M, Dirnagi U. Sulfonylureas improve outcome in patients with type 2 diabetes and acute ischemic stroke. Stroke. 2007; 38: 2526-2530.
12. Shook SJ, Gupta R, Vora NA, Tievsky AL, Katzan I, Krieger DW. Statin use is independently associated with smaller infarct volume in nonlacunar MCA territory stroke. J Neuroimaging. 2006;16:341-346.
13. Streifler JY. Statins, stroke outcome, and stroke prevention: when should we start treatment? [Editorial]. Stroke. 2004;35:1121-1123.
14. Glazier SS, O'Rourke DM, Graham DI, Welsh FA. Induction of ischemic tolerance following brief local focal ischemic in rat brain. J Cereb Blood Flow Metab. 1994;14:545-553.
15. Arboix A, Cabeza N, Garcia-Eroles L, Massons J, Oliveres M, Targa C, Balcells M. Relevance of transient ischemic attack to early neurological recovery after nonlacunar ischemic stroke. Cerebrovasc Dis. 2004;18:304-311.
16. Benavente O, White CL, Roldan AM. Small vessel strokes. Curr Cardiol Rep. 2005;7:23-28.
17. Ovbiagele B, Saver JL. Intensive statin therapy after stroke or transient ischemic attack: a SPARCLing success? Stroke. 2007;38:1110-1112.
18. Weih M, Amberger N, Wegener S, Dirnagl U, Reuter T, Einhaupl K. Sulfonylurea drugs do not influence initial stroke severity and in-hospital outcome in stroke patients with diabetes. Stroke. 2001;32:2029-2032.